Navigation Links
AutoGenomics Receives FDA Clearance for its INFINITI® CYP2C19 Assay
Date:10/26/2010

VISTA, Calif., Oct. 26 /PRNewswire/ -- AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its INFINITI® CYP2C19 Assay.  The test detects 3 genetic variants, *2, *3, *17, of the CYP450 2C19 gene and is to be used on the company's automated molecular testing platform, the INFINITI® Analyzer.  

"We are very excited to receive FDA clearance for our 2C19 test" said Fareed Kureshy, President and CEO of AutoGenomics. "The necessity of this genetic test has been implicated in literature now for several years.  The FDA has now provided clinicians with a tool in determining medical strategies for therapeutics that are metabolized by the CYP 450 2C19 gene test specifically * 2, *3, *17. This is an important milestone in the era of personalized medicine. Several of our customers are awaiting such clearance to implement testing in their practice." He further said, "we continue to expand our portfolio of FDA cleared products." "The INFINITI® CYP 450 2C19 test is unique in evaluating *17 which can help clinicians identify ultra metabolizers" said Robert Cole, MD., Chief Medical Officer at AutoGenomics

The INFINITI® System features a broad menu of 42 applications, with 5 FDA cleared products and 16 CE marked products.

About AutoGenomics

AutoGenomics Inc., a privately held company based in Vista, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of personalized medicine. www.autogenomics.com


'/>"/>
SOURCE AutoGenomics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AutoGenomics Invited to Present at Thomas Weisel Partners 2009 Healthcare Conference
2. AutoGenomics New RVP Assay Addresses Current Challenge to Detect Flu A - Swine H1N1
3. AutoGenomics Invited to Present at the 2009 JPMorgan Healthcare Conference
4. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
5. UCLA engineering receives $6M to construct new state-of-the-art building
6. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
7. EarlySenses EverOn(R) Central Display Station (CDS) Receives FDA Clearance
8. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
9. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for New Collagen Dental Membrane Based on Porcine Collagen Platform Technology
10. Xiaoguang Meng receives honorary master of engineering from Stevens
11. AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... York , March 22, 2017 ... largely fragmented, states a research report by Transparency Market ... Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted for ... 2015. The prominent players in this market are focusing ... their product portfolio, which is likely to lead to ...
(Date:3/22/2017)... ... ... Premier executive recruitment firm, Slone Partners, is proud to have been named a Top ... Hunt Scanlon Media is one of the most respected life science publications in the ... sector. , “It is a great honor for Slone Partners to be part of ...
(Date:3/22/2017)... , ... March 21, 2017 , ... The Conference Forum ... (CMO Summit) to be held on May 10-11, 2017, at the Colonnade Hotel in ... specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical ...
(Date:3/22/2017)... and PETACH TIKVAH, Israel , March ... a leading developer of adult stem cell technologies for ... Chief Executive Officer, will provide an update on new ... nd Annual Neuroscience Biopartnering and Investment Forum, being ... York Academy of Sciences. ...
Breaking Biology Technology:
(Date:3/6/2017)... , March 6, 2017 ... sales technology, today announced Predictive Sales Coach TM ... infusing actionable sales intelligence into Salesforce. This unique ... enable their sales organizations with deep knowledge of ... allow for intelligent engagement. Predictive Sales Coach extends ...
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
Breaking Biology News(10 mins):